Multimerization of a Proline-Rich Antimicrobial Peptide, Chex-Arg20, Alters Its Mechanism of Interaction with the Escherichia coli Membrane  by Li, Wenyi et al.
Article
Multimerization of a Proline-Rich Antimicrobial
Peptide, Chex-Arg20, Alters Its Mechanism of
Interaction with the Escherichia coli MembraneGraphical AbstractHighlightsd Multimers of the proline-rich antimicrobial peptide,
ChexArg20, were prepared
d Increase in peptide valency alters its Escherichia coli
membrane interaction
d Change is from membrane non-lytic to membrane disruption
d There is also simultaneous change from membrane
hyperpolarization to depolarizationLi et al., 2015, Chemistry & Biology 22, 1250–1258
September 17, 2015 ª2015 Elsevier Ltd All rights reserved
http://dx.doi.org/10.1016/j.chembiol.2015.08.011Authors
Wenyi Li, Neil M. O’Brien-Simpson,
Julien Tailhades, ...,
Frances Separovic,
Mohammed Akhter Hossain,
John D. Wade
Correspondence
john.wade@florey.edu.au (J.D.W.),
akhter.hossain@florey.edu.au (M.A.H.)
In Brief
Li et al. show that Escherichia coli
membrane interaction and permeability
of a designed proline-rich antimicrobial
peptide, Chex-Arg20, is significantly
altered by its covalent multimerization.
With an increase from monomer to
tetramer, the mechanism proceeds from
membrane aggregation and non-lysis to
membrane damage.
Chemistry & Biology
ArticleMultimerization of a Proline-Rich Antimicrobial
Peptide, Chex-Arg20, Alters Its Mechanism of
Interaction with the Escherichia coliMembrane
Wenyi Li,1,2 Neil M. O’Brien-Simpson,3,4 Julien Tailhades,2 Namfon Pantarat,3 RaymondM. Dawson,5 Laszlo Otvos, Jr.,6,7
Eric C. Reynolds,3,4 Frances Separovic,1,4 Mohammed Akhter Hossain,1,2,* and John D. Wade1,2,*
1School of Chemistry, University of Melbourne, VIC 3010, Australia
2The Florey Institute of Neuroscience and Mental Health, University of Melbourne, VIC 3010, Australia
3Oral Health CRC, Melbourne Dental School, University of Melbourne, VIC 3010, Australia
4Bio21 Institute, University of Melbourne, VIC 3010, Australia
5Land Division, Defence Science and Technology Organization, Fishermans Bend, VIC 3207, Australia
6Department of Biology, Temple University, Philadelphia, PA 19122, USA
7Institute of Medical Microbiology, Semmelweis University, Budapest 1089, Hungary
*Correspondence: john.wade@florey.edu.au (J.D.W.), akhter.hossain@florey.edu.au (M.A.H.)
http://dx.doi.org/10.1016/j.chembiol.2015.08.011SUMMARY
A3-APO, a de novo designed branched dimeric pro-
line-rich antimicrobial peptide (PrAMP), is highly
effective against a variety of in vivo bacterial infec-
tions. We undertook a selective examination of
the mechanism for the Gram-negative Escherichia
coli bacterial membrane interaction of the monomer
(Chex-Arg20), dimer (A3-APO), and tetramer (A3-
APO disulfide-linked dimer). All three synthetic pep-
tides were effective at killing E. coli. However, the
tetramer was 30-fold more membrane disruptive
than the dimer while the monomer showed no mem-
brane activity. Using flow cytometry and high-resolu-
tion fluorescent microscopy, it was observed that
dimerization and tetramerization of the Chex-Arg20
monomer led to an alteration in the mechanism of
action from non-lytic/membrane hyperpolarization
to membrane disruption/depolarization. Our findings
show that the membrane interaction and perme-
ability of Chex-Arg20 was altered by multimerization.
INTRODUCTION
The widespread emergence of multidrug-resistant (MDR) bacte-
rial infections has led to increased interest in the search for new
antibiotics (Gammon, 2014). Antimicrobial peptides (AMPs) are
considered as potential alternatives to conventional antibiotics,
as they possess broad-spectrum activity and distinct modes
of action that are based on their compositional and structural di-
versity (Jenssen et al., 2006). Most AMPs possess the ability to
disrupt bacterial membranes through the formation of different
pore structures as well as inhibiting intracellular targets, which
can occur without causing membrane disruption (Brogden,
2005; Zasloff, 2002). Among the various types of AMPs, pro-
line-rich AMPs (PrAMPs), which are typically found in insects
and higher-order animals, show particular efficacy against sys-1250 Chemistry & Biology 22, 1250–1258, September 17, 2015 ª201temic infections caused by Gram-negative bacteria. They dis-
play multimodal in vivo activity that include a combination of
cell-penetrating capacity, targeting of several intracellular com-
ponents including the 70-kDa bacterial heat shock protein
DnaK causing interference with bacterial protein folding, and
immunomodulatory activity (Li et al., 2014). Importantly, the
PrAMPs, apidaecins, Bac7, and oncosins, were recently shown
to bind with nanomolar dissociation constants to the 70S ribo-
some, leading to blockade of protein biosynthesis (Krizsan
et al., 2014; Mardirossian et al., 2014). Tertiary structural ana-
lyses have since shown that oncosin acts by simultaneously ob-
structing the peptidyl transferase center and the peptide-exit
tunnel of the ribosome (Roy et al., 2015; Seefeldt et al., 2015).
PrAMPS also have very low toxicity toward host cells (Li et al.,
2014). These features have highlighted the considerable poten-
tial of PrAMPs as replacements of, or supplements to, conven-
tional antibiotics.
The peptide, Chex-Arg20, was de novo designed based
on native PrAMPs with additional sequence optimization to
enhance bacterial membrane penetration (Otvos et al., 2005;
Rozgonyi et al., 2009). The branched dimeric form of A3-APO
displays extensive and potent activity against Gram-negative
bacteria including against MDR microbes in vitro, but also
decreases the mortality and bacterial load in mouse models
infected by MDR microbes in vivo (Ostorhazi et al., 2011a,
2011b; Otvos et al., 2014; Szabo et al., 2010). Furthermore, by
inhibiting the folding of enzymes responsible for bacterial resis-
tance, A3-APO in combination with conventional antibiotics
either partially or fully restores their lost activities against MDR
pathogens (Cassone and Otvos, 2010; Cassone et al., 2008;
Otvos et al., 2006). The ability of A3-APO to inhibit protein refold-
ing in bacteria also leads to decreased bacterial toxin production
in vitro and increased survival time in animal models (Otvos et al.,
2014).
A3-APO has been shown to degrade in vivo into several frag-
ments, including the single-chain analog Chex-Arg20 peptide
that exhibits equal or even better activity than its parental pep-
tide, depending upon the selected cell line in vitro and the infec-
tion model in vivo (Li et al., 2015; Noto et al., 2008; Ostorhazi
et al., 2013). To gain a better understanding of the mechanism5 Elsevier Ltd All rights reserved
Table 1. Structure and Activity of PrAMP Analogs
PrAMP Sequence MIC (mM) MBC (mM) MPC (mM)a
Monomer Chex-RPDKPRPYLPRPRPPRPVR NH2 28.6 ± 0.4 38.0 ± 0.9 >100
Dimer, A3-APO Chex-RPDKPRPYLPRPRPPRPVR
Chex-RPDKPRPYLPRPRPPRPVR
Dab NH2
13.2 ± 1.7 23.9 ± 3.8 15.0 ± 0.2
Tetramer
Chex-RPDKPRPYLPRPRPPRPVR
Chex-RPDKPRPYLPRPRPPRPVR
Dab C
2
S
NH2
22.6 ± 1.2 37.8 ± 0.1 0.5 ± 0.1
aFor conversion of MIC/MBC and MPC values into mg/l, use a multiplication factor of 2.5 for the monomer, 5 for the dimer, and 10 for the tetramer.of action, we undertook a detailed study using both flow cytom-
etry and high-resolution microscopy of the effect on the Escher-
ichia colimembrane of the Chex-Arg20 monomer, its dimer (A3-
APO). For the purpose of comparison, a novel tetramer, i.e., a
dimer of A3-APO connected by a disulfide bridge, was also
examined. The results revealed important mechanistic differ-
ences between the three peptides, with important implications
for the design of novel PrAMPs.
RESULTS AND DISCUSSION
Synthesis of Chex-Arg20 Multimer Analogs
The Chex-Arg20 monomer and its A3-APO dimer were synthe-
sized by solid-phase peptide synthesis as previously described
(Otvos et al., 2005). A similar synthesis approach involving an
additional round of 3,30-diaminobenzidine (DAB) branching was
initially used for the synthesis of the tetramer. However, target
peptide could not be obtained for each of the chemical strategies
trialed, e.g., decreasing the resin loading, changing resin type,
and replacing Lys with DAB. For this reason, a simple strategy
of disulfide-mediated dimerization was used. A3-APO was thus
assembled containing an additional cysteine at the C terminus
(Figure S1; 1). A portion was subjected to Cys thiol activation
by 2,20-dithiobis(5-nitropyridine) (DTNP) to yield 2 (Figure S1;
2). The tetramer (dimerization of A3-APO) (Figure S1; 3) was ob-
tained by the combination of (1) and (2) in guanidine hydrochlo-
ride buffer (pH 8.5) in quantitative yield (Figure S1). All peptides
were subjected to comprehensive chemical characterization
by analytical reversed-phase high-performance liquid chroma-
tography (RP-HPLC) and MALDI-TOF mass spectrometry to
confirm their high purity (Figure S2).
Antibacterial Assay and E. coli Membrane Action
Eachpeptide (monomer, dimer, and tetramer)was tested for anti-
bacterial activity against the Gram-negative bacterium E. coli
in Luria-Bertani broth (LB). The minimum inhibitory concentra-
tion (MIC) and minimum bactericidal concentration (MBC)
were determined, and microbial flow cytometry was used to
monitor membrane integrity/permeability to the fluorescent dye
propidium iodide (PI) (membrane permeabilizing concentration
[MPC]) (Lo´pez-Amoro´s et al., 1995) for each peptide (Figure S3).Chemistry & Biology 22, 1250–125TheMICwasdeterminedbyplottingmaximal growth versus pep-
tide concentration, according to the Lambert and Pearson anal-
ysis method, while MBC was confirmed via colony-forming unit
(CFU) measuring assay (Lambert and Pearson, 2000; Sani
et al., 2013). TheMICandMBCvalues for themonomer anddimer
were similar to that inducedby the tetramer (Table 1). However, to
investigate themode of antibacterial action, we used flowcytom-
etry to measure the membrane integrity of E. coli incubated with
the peptides, and found that the tetramer had a significantly (p <
0.01) lower MPC value than the monomer or dimer (Table 1). The
MIC, MBC, andMPC values for A3-APO were found to be statis-
tically equivalent but, conversely, the monomer failed to induce
persistent membrane permeabilization. Figures 1A, 1B, 1C, and
S3 show representative flow cytometry plots of E. coli incubated
with each peptide at various concentrations, and clearly indicate
that both A3-APO and the tetramer permeabilized the bacterial
membrane whereas the monomer, even at the highest con-
centration tested, did not. The mechanism of action reported
for themonomer is binding and inhibiting the function of a number
of cytosolic bacterial proteins (Cassone et al., 2008). Thus,
the lack of membrane permeabilization caused by the monomer
is consistentwith these findings. A3-APOhas also been shown to
bind and inhibit cytosolic protein folding and function (Zahn et al.,
2013). However, our data also confirm that it has an additional
mode of action, that of membrane permeabilization. The consis-
tency between the MIC, MBC, and MPC values for A3-APO
indicates that no one mechanism is dominant and that there is,
probably, synergy between the modes of antibacterial actions.
Interestingly, the flow cytometry data, but not the growth-
based assays, clearly demonstrated that multimerization of
the Chex-Arg20 monomer into A3-APO and the tetramer alters
the mode of action from non-lytic to a membrane disruptive
capacity.
Despite the very potent membrane permeabilizing activity of
the tetramer, the MIC and MBC values were higher and equiva-
lent to Chex-Arg20 monomer and A3-APO (dimer) (Table 1).
Apart from valency, the sole difference between the tetramer
and A3-APO is the disulfide bridge used to attach two A3-APO
peptides together forming the tetramer. Antimicrobial peptides
that are known to induce membrane disruption act on the in-
ner/cytoplasmic membrane, which is known to contain disulfide8, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1251
Figure 1. Graphical Representation of the Determination of the MPC
(A) Monomer, (B) A3-APO, and (C) tetramer against E. coli preincubated at 37C, in which viable whole cells (region 1, SYTO9+ cells), deadwhole cells (region 2, 3,
PI+ cells), and cell debris (region 4, SYTO9 and PI). See also Figure S3.bond-reducing proteins and have a redox potential that favors
disulfide bond disruption (Eser et al., 2009; Kadokura et al.,
2003). Furthermore, the bacterial membrane is highly fluid and
dynamic, and the lytic action of some AMPs has been shown
to be reversible (Gee et al., 2013; Hall et al., 2014; Lee et al.,
2014). Thus the decline in activity from that measured by flow cy-
tometry (MPC) and that measured by the growth assays (MIC
and MBC) is probably due to two factors: the fluid/dynamic na-
ture and disulfide bond-reducing environment of the inner mem-
brane. To assess this possibility, the MPC against E. coli of the
membrane-active tetramer was evaluated at different times of in-
cubation, and compared with control AMPs. The time course
showed that the concentration of tetramer needed to disrupt
the bacterial membrane increased as a function of incubation
time, which suggests that reduction of the disulfide bond
occurred on culture with E. coli (Figure 2A). As further evidence,
samples of the tetramer and bacteria co-cultured after 14 hr
were lysed via sonication, and both tetramer and degraded
products were isolated and analyzed by RP-HPLC. The two prin-
cipal peaks were identified as corresponding to tetramer and A3-
APO-Cys (Figure 2B).
These results show that the tetramer rapidly permeabilizes
the membranes of Gram-negative bacteria at a significantly
lower concentration than the A3-APO (dimer). However, the inner
membrane environment leads to disulfide bond reduction of the
tetramer to its A3-APO (dimer) components and an apparent
decrease in antimicrobial activity (MIC, MBC), albeit to the
same level as the dimer. Given that tetramer reduction is only
about 50% complete after 14 hr, it is to be expected that the
assay results will reflect a mixture of degradation outcomes.
Furthermore, the breakdown of the tetramer itself is not simple
and does not lead to two identical A3-APOmolecules, but rather
to modified A3-APO that contain a terminal Cys residue. This will
mean they will not have the same AMP activity as shown in the
previous study (Li et al., 2015). Therefore, the observed decrease
in activity of the reduced tetramer is a partial reflection of the
reduced/modified version simply not behaving as an A3-APO
molecule. Given the complex interactions shown by A3-APO in
killing bacteria, this would have an impact on activity. Work is un-
der way on the preparation of a non-reducible tetramer. These
results similarly indicate that the bacterial membrane is not a1252 Chemistry & Biology 22, 1250–1258, September 17, 2015 ª201static environment, and the capacity of the disulfide bond to
be reduced within the inner membrane interface of bacteria, as
well as being an important factor in AMP design, also suggests
a useful strategy for delivery of drugs via antimicrobial peptides.
Reversible disulfide linkages have been extensively utilized in
drug discovery to release final drug compositions from prodrugs
(Saito et al., 2003).
Peptide Localization in E. coli
Given that the mechanism of membrane action of Chex-Arg20
varies with the extent of multimerization, we used both flow cy-
tometry and high-resolution microscopy to determine whether
the interaction of peptide and bacteria correlates withmembrane
lysis and to determine where the peptides localize in the bac-
teria. Fluorescent analogs of the peptides were prepared via
the metal-free thiol-maleimide coupling reaction (Nguyen et al.,
2013; Pounder et al., 2008). A fluorescein label, fluorescein iso-
thiocyanate (FITC), was judiciously placed at the C terminus of
each peptide, which were then co-cultured with E. coli and
analyzed by flow cytometry with additional PI fluorescence to
indicate membrane disruption (Figure S4). The uptake of FITC-
peptide and PI was calculated by the ratio of the green fluores-
cein fluorescence or the red PI fluorescence to total fluorescence
population (Figure 3). The addition of the fluorophore did not
lead to significant inactivation of the peptides (Table S1). With
increasing peptide concentration, there was a corresponding in-
crease in FITC-monomer associated with E. coli cells, with 100%
FITC-monomer-positive bacteria correlating with the MIC and
MBC (Figure 3, see also Table S1). Consistent with the monomer
MPC data, there was no uptake of the membrane-permeable in-
dicator dye, PI, with increasing monomer concentration. FITC-
A3-APO and FITC-tetramer showed a similar trend of bacterial
uptake of peptide compared with the labeled monomer. How-
ever, for both peptides there was a corresponding increase in
PI-positive bacteria, which is consistent with the ability of A3-
APO and the tetramer to induce membrane lysis (Figure 3).
Hence, as determined by PI inclusion, themembrane lytic mech-
anism of A3-APO and the tetramer correlates with peptide asso-
ciation for bacteria and is related to the concentration depen-
dence for the mechanism alteration (Hernandez-Gordillo et al.,
2014; Paulsen et al., 2013; Podda et al., 2006; Ve´gh et al.,5 Elsevier Ltd All rights reserved
Figure 2. Stability of Tetramer in E. coli Culture
(A) MPC time course of tetramer. Data are expressed as the concentration of peptide (mM) that causes 100%of bacterial cells to have a permeabilized membrane
(triangles).
(B) RP-HPLC of the tetramer co-cultured with E. coli. Lysate of: (1) E. coli only, (2) E. coli incubated with the tetramer after 90 min, and (3) after 14 hr incubation.
Calculated [M + H]: tetramer = 10,270.5; A3-APO-Cys-NH2 = 5136.1.2011). A trend analysis on the FITC-peptide-positive bacteria
and PI-positive bacteria found that there was a significant (p <
0.01) positive correlation between membrane disruption and
peptide-bound bacteria for A3-APO (R2 = 0.98) and tetramer
(R2 = 0.97) but not for the monomer (R2 = 0.27).
The flow cytometry data showed that the monomer, dimer,
and tetramer each associate with the bacteria, but did not
show where each peptide localized with increasing concentra-
tion. To investigate this aspect, Alexa Fluor 647-labeled pep-
tides were assembled using the same chemistry as described
above. Alexa Fluor dyes are superior to FITC in that they
have longer photo-bleaching half-life and are thus suitable for
high-resolution microscopy. Addition of the Alexa Fluor label
to the peptides had the same effect as FITC on peptide antimi-
crobial activity (Table S1). For image analysis, E. coli mem-
branes were labeled with FM lipophilic styryl dye (FM 4-64FX,
green fluorescence) and incubated (same times as above)
with the Alexa Fluor 647-labeled peptides (red fluorescence),
and the peptide-bacteria interaction then was visualized using
an Applied Precision Deltavision OMX V4 Blaze structured illu-
mination microscope (Figure 4; a yellow/orange fluorescence
indicates co-localization of peptide and membrane). With
increasing concentrations (6–24 mM), the Alexa Fluor 647-
monomer initially localized to the membrane of the bacteria,
and as the peptide concentration increased the fluorescence
of the membrane increased (Figure S5). Although the monomer
is evidently localized at the membrane at all concentrations
tested, it is also apparent that it is within the cytoplasm, ap-
pearing as discrete foci (red spots). At a concentration of
6 mM, the peptide can also be seen to be only within the cyto-
plasm, as indicated by the bacteria with a green fluorescent
membrane and red fluorescent spots within the bacteria (Fig-
ure S5). These results are consistent with previous reports
that the monomer is known to bind to cytoplasmic proteins
and inhibit their function, resulting in the death of the bacteria
(Zahn et al., 2013). Compared with the monomer, both labeledChemistry & Biology 22, 1250–125A3-APO and tetramer initially interact with the bacterial mem-
brane at the lowest concentration (6 mM), causing membrane
disruption, as evident from the ruffling and broken staining of
the bacteria (Figures S5B and S5C). As peptide concentration
increased, both A3-APO and tetramer localized primarily in
the cytosol, then, at higher concentrations, the peptides asso-
ciated with both the cytosol and membrane. Interestingly, both
A3-APO and the tetramer have a similar pattern of localization
compared with the known cell-penetrating peptide Arginine-9
(Figure S5D). Our data clearly show that the Chex-Arg20 mono-
mer, A3-APO, and tetramer all interact with the membrane of
the bacteria, and that they localize to the cytosol of the bacteria
as the peptide concentration increases. It is clear that mem-
brane interaction of A3-APO and the tetramer induce mem-
brane lysis, whereas the monomer does not. However, the
monomer clearly interacts with the bacterial membrane; to
investigate whether the monomer affects the bacterial mem-
brane, the membrane potential of the bacteria incubated with
each of the peptides was analyzed.
Analysis of Membrane Potential
A number of non-lytic traditional antibiotics, such as gramicidin
and valinomycin, act as ionophores, allowing diffusion of specific
ions across themembrane and down concentration gradients by
forming ion channels (Harold and Baarda, 1967; Separovic et al.,
1994). This facilitated diffusion of ions results in alteration of the
membrane potential, causing depolarization of the membrane,
which is typical of gramicidin and pore-forming or lytic AMPs
(Wu et al., 1999), whereas valinomycin, although acting as a
K+-specific ionophore, induces a hyperpolarized membrane
state in low K+ environments. Some highly cationic AMPs have
been reported to produce a hyperpolarized membrane by lying
on top of the lipid membrane (Hong and Su, 2011).
The membrane potential of E. coli with the peptides was
measured using the Invitrogen BacLight bacterial membrane
potential kit to determine the capacity of the peptides to alter8, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1253
Figure 3. Percentage Uptake of Fluorescein-Labeled Peptides
(A) FITC-monomer-treated E. coli, (B) FITC-A3-APO-treated E. coli, (C) FITC-tetramer-treated E. coli. The percentage of peptide-positive bacteria (FITC+) and
membrane-disrupted bacteria (PI+) were determined by flow cytometry. Crosses indicate membrane-disrupted bacteria (PI+); triangles indicate peptide-positive
bacteria (FITC+). All data are expressed as mean ± standard deviation as indicated by the error bars, based on values obtained from at least two biological
replicates. See also Figure S4.membranepotential. Bacteriawere incubatedwith eachpeptide
at half, equal, and double the MIC, stained with the membrane
potential (ion sensitive/response) fluorophore 3,30-diethyloxa-
carbocyanine iodide (DiOC2), and membrane potential was
determined by flow cytometry (Figure S6). The E. coli normal
membrane potential state (CCCP) and fully depolarized state
after incubation with carbonyl cyanide 3-chlorophenylhydra-
zone (+CCCP) are shown in Figures S6A and S6B, respectively.
From the flow cytometry dot plots, each peptide can be seen
to have distinct actions on E. coli membranes. The increase in
red fluorescence in the bacterial population incubated with the
monomer compared with the normal/untreated cells is indica-
tive of a hyperpolarized membrane. A3-APO increased the red
fluorescence also but induced a shift in the green fluorescent
population aspeptide concentration increased, indicating a shift
from a mixed hyperpolarized and depolarized cell population
to a more depolarized membrane population. The effect of the
tetramer on E. coli was to induce a depolarized cell population.
Figure 5 shows the calculated membrane potential and clearly
demonstrates that themonomer led to a strongly hyperpolarized
state, and A3-APO to a depolarized state, while the tetramer
induced a strongly depolarized population. The ability of the
monomer to induce a hyperpolarized membrane indicates that
these peptides clearly have more than one mode of antimicro-
bial action, which is consistent with previous reports that both
the monomer and A3-APO also bind to cytosolic proteins and
induce cell death via this mechanism (Cassone et al., 2008),
but here it is shown that both these peptides alter themembrane
potential with the monomer having a potential ionophore mech-
anism, whereas both A3-APO and the tetramer have a mem-
brane-depolarizing/lytic function. The ability of the monomer
to hyperpolarize bacterial membranes may increase suscepti-
bility to host antimicrobial peptides. Indeed, Gries et al. have
shown that bacteria with hyperpolarized membranes are
more susceptible to cationic antimicrobial peptides (Gries
et al., 2013). This mechanism may in part explain the finding
that the monomer and A3-APO are more effective in vivo (Osto-
rhazi et al., 2011a, 2011b; Otvos et al., 2014; Szabo et al., 2010),
as a bacterial infection would induce the release of AMPs from
host cells such as neutrophils.1254 Chemistry & Biology 22, 1250–1258, September 17, 2015 ª201General Discussion
There remains no universal agreement within the AMP research
community as to the precise mechanism of AMP membrane
interaction and corresponding antibacterial activity. However,
Vivcharuk and Kaznessis (2010) showed that an AMP dimer
has greater peptide-membrane attraction than the monomer
counterpart. Therefore, we believe a plausible explanation for
our findings is that a dimer/tetramer has a wider, highly positively
charged ‘‘carpet-like’’ surface leading to increased binding. This
is supported by our results showing clearly that the monomer
does interact with the membrane (high-resolution microscopy
imaging and membrane potential assay); moreover, as valency
is increased there is a corresponding increase in the attraction
of the multimer to the membrane and, hence, a change in mech-
anism from non-disruptive to disruptive.
Finally, there are few other examples of the effects of dimeriza-
tion or multimerization on other PrAMPs. It previously shown that
the PrAMP, pyrrhocoricin, was more active as a dimer, an effect
attributed to better efficacy on bacterial membranes (Cudic et al.,
2002). This formed the basis of our many studies on A3-APO and
its analogs. Furthermore, Dempsey et al. (2003 and Zhou et al.
(2011) showed that a dimer of a peptide monomer becomes
more membrane disruptive. Hernandez-Gordillo et al. (2014)
also showed that a dimer of another designed PrAMP possessed
increased antibacterial potency. At MIC, it showed no bacterial
membrane disruption but did cause rupture at higher concentra-
tions. It remains to be determined whether this can be shown for
PrAMPs in general, but we anticipate that our results will provide
significant motivation for others to examine this possibility.
In summary, multimerization of the designed PrAMP, Chex-
Arg20, leads to an alteration in the mechanism of interaction
with the membrane of the Gram-negative bacterium E. coli.
With an increase frommonomer to tetramer, themechanism pro-
ceeds from membrane aggregation and non-lysis to membrane
damage, as indicated by MPC via flow cytometry and image
analysis by high-resolution microscopy. Meanwhile, the mem-
brane potential assay showed that the monomer hyperpolarized
the bacterial membrane while the dimer caused membrane
polarization that changed to depolarization as concentration
increased. Furthermore, the tetramer displayed a much more5 Elsevier Ltd All rights reserved
Figure 4. Representative Image Analysis of Alexa Fluor 647-Labeled Peptide at 12 mM, Co-cultured with E. coli
Applied Precision Deltavision OMX V4 Blaze Structured Illumination Microscope used with membrane stain FM4-64FX dye (green) and Alexa Fluor 647 (red)
labeledmonomer, A3-APO, tetramer, and Arginine-9 treated samples. Lipidmembranes are shown as green fluorescence; red fluorescence indicates Alexa Fluor
647-labeled peptide; yellow/orange fluorescence indicates co-localization of lipid membrane and peptide. See also Figure S5.potent ability to depolarize membranes, even at low concentra-
tion. Importantly, none of the peptides display hemolytic activity
or cytotoxicity (Table S2). These findings aid the understanding
of the action of PrAMPs with multiple mechanisms of actionChemistry & Biology 22, 1250–125as well as novel cell-penetrating peptides. For example, the
increased membrane rupture by dimers and tetramers suggests
that covalent combination with conventional antibiotics may
enable a more effective means of bacterial killing, which might8, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1255
Figure 5. Detection of Membrane Potential in E. coli with Serial
Peptide Addition
Red/green ratios were calculated using mean fluorescence intensities of
populations incubated with 30 mMDiOC2 for 30min in the presence or absence
of CCCP and with 0.53 MIC, 13 MIC, and 23 MIC of monomer, A3-APO, or
tetramer. All data are expressed as mean ± standard deviation as indicated by
the error bars, based on values obtained from at least two biological replicates.
See also Figure S6.not otherwise be possible with the monomer. Furthermore, a
dimer of two different PrAMPsmay afford greater bacterial killing
selectivity or intracellular targeting.
SIGNIFICANCE
The widespread emergence of antibiotic resistance and the
paucity of novel and effective treatments have stimulated
much interest in antimicrobial peptides as potential thera-
peutics. In particular, PrAMPs, which are widely distributed
in Nature, have a distinct portfolio of activity ranging from
membrane rupture to blockade of ribosomal protein expres-
sion. This work sought to understand the mode of interac-
tion with Gram-negative E. coli membrane interaction of
the de novo designed PrAMP, Chex1-Arg20, and its discon-
tinuous dimer, A3-APO, and of their permeability. For com-
parison, a disulfide dimer of A3-APO was also examined.
The data showed that an increase in valency led to an alter-
ation in the mechanism of action from non-lytic/membrane
hyperpolarization to membrane disruption/depolarization.
Furthermore, the E. coli membrane potential displayed dif-
ferences between Chex1-Arg20 and multimers. This change
in capacity was not correlated by proportional bacterial
killing, highlighting the essential roles of other intracellular
or immunological mechanisms in this process. Neverthe-
less, the distinctive, altered properties of these multimers
advance our understanding of this type of AMP and suggest
significant potential for the development of novel PrAMPs.
EXPERIMENTAL PROCEDURES
Materials
9-Fluoroenylmethoxylcarbonyl (Fmoc)-L-amino acids and N,N,N0,N0-tetra-
methyl-O-(1H-benzotriazol-1-yl)uranium-hexafluorophosphate (HBTU) were1256 Chemistry & Biology 22, 1250–1258, September 17, 2015 ª201purchased from GL Biochem. TentaGel-MB-RAM-resin and TentaGel-R-
RAM-resin were from Rapp Polymere. N,N-Diisopropylethylamine (DIPEA),
dimethylformamide, and trifluoroacetic acid (TFA) were obtained from
Auspep. Piperidine, triisopropylsilane (TIPS), anisole, 3,6-dioxa-1,8-octanedi-
thiol (DODT), DTNP, and acetonitrile were all obtained from Sigma. Fluores-
cein-5-maleimide, FM4-64FX dye, Alexa Fluor 647-maleimide, SYTO9, and
PI were purchased from Life Technology.
Solid-Phase Peptide Synthesis
The peptides (Table 1) were synthesized by Fmoc solid-phase methods (Fields
and Noble, 1990). Peptide-chain assembly was carried out on a CEM Liberty
(DKSH) microwave-assisted synthesizer or a Protein Technologies Tribute
batch-wisepeptide synthesizer using FmocRink amide polystyrene resin. Stan-
dard Fmoc chemistry was used throughout with a 4-fold molar excess of the
Fmoc-protected amino acids in the presence of 4-fold HBTU and 8-fold
DIPEA. Non-natural amino acids were coupled manually to ensure completion
of coupling reaction. The peptides were cleaved from the solid-support polysty-
rene resin with TFA in the presence of anisole, TIPS, and water as scavengers
(ratio 95:3:1:1) for 2 hr at room temperature. After cleavage the resin was
removed by filtration, the filtrate was concentrated under a stream of nitrogen,
and the peptide products were precipitated in ice-cold diethyl ether, washed,
and centrifuged three times. The peptides were then purified by RP-HPLC in
water and acetonitrile with 0.1% TFA. The final products were monitored and
characterized by RP-HPLC and MALDI-TOF mass spectroscopy. The tetramer
was obtained by disulfide bond linkage between twomolecules of A3-APO (see
Supplemental Experimental Procedures). Peptide labeling with fluorescein-5-
maleimide or Alexa Fluor 647-maleimide was achieved in the presence of pep-
tide with PBS at pH 7.4 (see Supplemental Experimental Procedures).
Peptide Localization with E. coli ATCC 25922
Before the test, for the normal peptide, both SYTO9 and PI were added. By
contrast, only PI was added to the fluorescein-labeled peptide samples. A3-
APO and fluorescein-labeled monomer/A3-APO in LB (100 ml, from initial stock
suspensions of 100 mM), 23 105 viable bacterial cells (100 ml of stock suspen-
sion, 2 3 105 CFU) were added and the mixtures, in 96-well flat-bottomed
microtiter plates (Interpath Service) were incubated at 37C for 90 min. The
contents of the 96-well plates were monitored by Quanta flow cytometry.
Image Analysis
E. coli was grown in LB. Viable cells were diluted to 2.53 105 cells/ml in LB at
37C immediately prior to incubation with Alexa Fluor 647-labeled peptides for
90 min. The co-culture samples were combined with labeled peptides at 6, 12,
or 24 mM. The samples were then transferred to Eppendorf tubes, followed by
washing with Hank’s balanced salt solution (HBSS; Invitrogen) three times
(5000 3 g, 10 min at 4C). The membrane stain FM4-64FX dye (Invitrogen)
(5 mg/ml, 10 min, ice bath) was added to the above samples to bind the outer
leaf of E. coli plasma membrane, followed by washing with HBSS three times
(5000 3 g, 10 min at 4C). Finally, the samples were transferred to chambers
coated with poly-D-lysine followed by fixation with 4% paraformaldehyde. Af-
ter sample preparation, the samples were analyzed by an Applied Precision
Deltavision OMX V4 Blaze structured illumination microscope (microscope la-
sers for FM4-64FX [568 nm] and Alexa Fluor 647 [642 nm] and filters: 609/37 for
FM4-64FX and 683/40 for Alexa Fluor 647) (Figure S5). SoftWorx software was
used for reconstruction and the Deltavision OMXMaster Control Software was
used for controls. Immersion oil with a refractive index of 1.514 was used for
the microscope.
Membrane Potential Assay
Membrane potential was determined by flow cytometry using a BacLight Bac-
terial Membrane Potential Kit (Invitrogen). E. coli was inoculated to late expo-
nential phase. Viable cells were then diluted to 2 3 106 cells/ml in PBS and
incubated at 37C with variable concentrations (0.53 MIC, 13 MIC, 23 MIC)
of the tested peptides. The protonophore CCCP was added with final concen-
tration 5 mM to the non-treated cells to provide a depolarized control, and
30 mM DiOC2 was added to the rest of the samples. Membrane potential
was determined by a flow cytometer as a ratio of the fluorescent cells between
the red and green fluorescence. Gates were drawn based on the controls pre-
sent in hyperpolarized, polarized, or depolarized regions.5 Elsevier Ltd All rights reserved
After analysis and collection of the data, the membrane potentials were
determined and normalized by the ratio of the population of red fluorescence
(FL3) to green fluorescence (FL1) intensity (Figure S6).
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